Patient-Reported Quality of Life Outcomes after Moderately Hypofractionated and Normofractionated Proton Therapy for Localized Prostate Cancer.
EPIC-50
moderately hypofractionation
prostate cancer
proton therapy
quality of life
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
20 Jan 2022
20 Jan 2022
Historique:
received:
15
12
2021
revised:
12
01
2022
accepted:
18
01
2022
entrez:
15
2
2022
pubmed:
16
2
2022
medline:
16
2
2022
Statut:
epublish
Résumé
We retrospectively evaluated the three-year patient-reported quality of life (QOL) after moderately hypofractionated proton therapy (MHPT) for localized prostate cancer in comparison with that after normofractionated PT (NFPT) using the Expanded Prostate Cancer Index Composite-50. Patients who received MHPT (60-63 Gy (relative biological effectiveness equivalents; RBE)/20-21 fractions) (
Identifiants
pubmed: 35158785
pii: cancers14030517
doi: 10.3390/cancers14030517
pmc: PMC8833499
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Japan Society for the Promotion of Science
ID : 20K16830
Références
Int J Radiat Oncol Biol Phys. 2002 Jan 1;52(1):6-13
pubmed: 11777617
Int J Urol. 2019 Oct;26(10):971-979
pubmed: 31284326
Cancer Med. 2018 Mar;7(3):677-689
pubmed: 29441697
Acta Oncol. 2017 Jul;56(7):963-970
pubmed: 28514929
Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):444-53
pubmed: 17513063
Cancer. 2013 May 1;119(9):1729-35
pubmed: 23436283
JAMA. 2017 Mar 21;317(11):1141-1150
pubmed: 28324092
Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):1021-31
pubmed: 11429230
J Clin Oncol. 2018 Oct 11;:JCO1801097
pubmed: 30307776
Cancer Treat Rev. 2016 Jul;48:50-60
pubmed: 27347670
Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1013-5
pubmed: 15519768
Lancet Oncol. 2016 Aug;17(8):1047-1060
pubmed: 27339115
J Clin Oncol. 2016 Jul 10;34(20):2325-32
pubmed: 27044935
Lancet Oncol. 2016 Apr;17(4):464-474
pubmed: 26968359
J Radiat Res. 2012;53(1):1-9
pubmed: 21997195
JAMA Oncol. 2019 May 1;5(5):664-670
pubmed: 30763425
Int J Clin Oncol. 2018 Apr;23(2):353-360
pubmed: 29098520
Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):95-102
pubmed: 27084632
Int J Radiat Oncol Biol Phys. 2019 Nov 15;105(4):713-722
pubmed: 31199994
Int J Radiat Oncol Biol Phys. 2011 Oct 1;81(2):552-9
pubmed: 21300457
N Engl J Med. 2016 Oct 13;375(15):1425-1437
pubmed: 27626365
Lancet Oncol. 2015 Dec;16(16):1605-16
pubmed: 26522334
Int J Radiat Oncol Biol Phys. 2019 Mar 15;103(4):823-833
pubmed: 30458234
Int J Part Ther. 2019 Summer;6(1):1-9
pubmed: 31773043
Urology. 2000 Dec 20;56(6):899-905
pubmed: 11113727
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):946-53
pubmed: 24139077
Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):e329-36
pubmed: 21703781
Med Care. 2003 May;41(5):582-92
pubmed: 12719681
J Clin Oncol. 2017 Jun 10;35(17):1884-1890
pubmed: 28296582
Australas Phys Eng Sci Med. 2016 Sep;39(3):645-54
pubmed: 27271800
J Exp Clin Cancer Res. 2009 Aug 19;28:117
pubmed: 19689825